The long-acting glucagon-like peptide-1 receptor agonist dulaglutide acts by stimulating insulin secretion and reducing glucagon levels in a glucose-dependent manner both in the fasting and postprandial states, resulting in reductions of both fasting glucose (FG) and postprandial glucose (PPG). In contrast, the main mechanism of action
of basal insulin is to reduce elevated FG by inhibiting hepatic glucose production.
The aim of the present post hoc analysis of the phase 3 AWARD-2 trial was to investigate whether specific baseline glycaemic patterns respond differentially to dulaglutide compared to insulin glargine (glargine). We categorized participants into four subgroups based on prespecified glucose thresholds and their baseline FG and daily Appropriate glucose control has to be achieved through reductions in both elevated fasting glucose (FG) and postprandial glucose (PPG), since both contribute to high glycated haemoglobin (HbA1c) levels and the development of complications in type 2 diabetes (T2D). 1, 2 The long-acting insulin analogue, insulin glargine (glargine), exerts its action primarily through a decrease in hepatic glucose production and consequent lowering of FG. 3 However, it has smaller effects on PPG and PPG excursions. 4 By contrast, once-weekly glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as dulaglutide, act by stimulating insulin secretion and reducing glucagon levels in both the fasting and postprandial states, thus reducing both FG and PPG levels. Additionally, GLP-1RAs contribute to a delay in gastric emptying, which has a role in further reducing PPG. [5] [6] [7] Due to the specific mechanism of action of insulin and GLP-1RAs, it is conceivable to expect differential responses to each treatment according to baseline glycaemic patterns. In the phase 3 Assessment of Weekly Administration of LY2189265 in Diabetes-2 (AWARD-2) trial, dulaglutide 1.5 mg demonstrated greater reductions in HbA1c with better weight control and less hypoglycaemia compared with glargine. 8 The aim of the present non-prespecified post hoc analysis was to investigate the efficacy of dulaglutide versus glargine at 52 weeks in participants from the AWARD-2 trial with different glycaemic patterns. Specifically, drug-induced changes in HbA1c at different combinations of baseline values of FG and daily 2-hour mean PPG were examined, with a particular focus on participants who had predominantly high FG and low PPG levels and those who had predominantly low FG and high PPG levels.
| METHODS

| Study design
Participants (n = 766) from the AWARD-2 clinical trial, which compared efficacy and safety of once-weekly dulaglutide with daily glargine, were included in this post hoc analysis. The AWARD-2 study design and results have been previously published. 8 For this post hoc, non-prespecified analysis, participants treated with dulaglutide or glargine were categorized into the following subgroups, according to glucose levels, measured by self-monitored plasma glucose, 
| Statistical analyses
| Change in HbA1c
At 52 weeks, significant reductions from baseline in HbA1c were observed in all subgroups with dulaglutide 1.5 mg and with glargine (all P < .05), except in the low FG/low PPG subgroup with glargine ( Figure 1A) . Overall, the greatest reductions were observed in the high 
| Change in FG and PPG
At 52 weeks, significant reductions from baseline in FG were observed in all subgroups with dulaglutide 1.5 mg and with glargine (all P < .05), except in the low FG/low PPG subgroup with dulaglutide 1.5 mg ( Figure 1B and Table S1 ). Overall, the greatest reductions were observed in the high FG/high PPG subgroup (dulaglutide 1.5 mg: Figure 1B and Table S1 ]).
Observed differences between the two treatments were not significant within any subgroup.
At 52 weeks, significant reductions from baseline in PPG were observed in all subgroups with dulaglutide 1.5 mg and with glargine (all P < .05), except in the low FG/low PPG subgroup with glargine ( Figure 1C and Table S1 ). Overall, the greatest reductions were observed in the high FG/high PPG subgroup (dulaglutide 1.5 mg: 
| Change in body weight
At 52 weeks, treatment with dulaglutide 1.5 mg was associated with significant reductions in body weight from baseline across all subgroups, while treatment with glargine was associated with significant increases in body weight from baseline in participants with low FG/low PPG, low FG/high PPG and high FG/high PPG ( Figure 1D ). Similar baseline characteristics were observed in participants treated with dulaglutide 0.75 mg; however, dulaglutide 0.75 mg was associated with greater reduction in HbA1c from baseline compared to glargine only in the low FG/low PPG subgroup ( Figure S2A ). In the high FG/high PPG subgroup, observed FG reductions were significantly greater with glargine than with dulaglutide 0.75 mg (P < .05; Figure S2B and Table S2 ), whereas observed reductions in PPG were similar among the two treatments across all subgroups ( Figure S2C and Table S2 ). Treatment with dulaglutide 0.75 mg was associated with significantly reduced body weight across all subgroups ( Figure S2D ).
| Safety
The complete safety profile for AWARD-2 was previously reported. 8 At 52 weeks, observed documented symptomatic hypoglycaemia was consistently lower with dulaglutide 1.5 mg versus glargine (Table S3 ). Table S3 ]).
Similar safety results were observed in participants treated with dulaglutide 0.75 mg (Table S4 ).
| DISCUSSION
In the present post hoc analysis, we investigated the efficacy of once- The greatest reduction overall in HbA1c was observed in the high FG/high PPG subgroup for both treatments. This subgroup was also associated with higher baseline HbA1c levels, and thus greater HbA1c reductions were to be expected. As suggested by previous reports, 10, 11 our initial hypothesis was that glargine would be associated with better efficacy over dulaglutide in the subgroup with prevalent high FG at baseline, whereas dulaglutide would be associated with predominant efficacy over glargine in the subgroup with prevalent high PPG at baseline. However, dulaglutide 1.5 mg was associated with higher HbA1c reductions than glargine also in the high FG/low PPG subgroup, even though observed FG levels at 52 weeks tended to be lower with glargine than with dulaglutide 1.5 mg, reflecting the greater effect of FG-driven basal insulin titration on fasting hyperglycaemia. The observed results could potentially be explained by dulaglutide reducing both FG and PPG, as well as glucose levels throughout the day, as demonstrated across the phase 3 clinical trials with this GLP-1RA. 8, [12] [13] [14] [15] [16] The superiority of dulaglutide 1.5 mg in reducing HbA1c, however, was also observed in the larger group with both high FG and high PPG at baseline, and is consistent with the overall study results. Nevertheless, the observed efficacy of dulaglutide 1.5 mg in reducing PPG can be appreciated in the low FG/high PPG subgroup, in which dulaglutide 1.5 mg was associated with greater PPG reductions than glargine.
Across subgroups, dulaglutide was associated with statistically greater body weight reductions compared to the weight gain observed with glargine, consistent with results reported in the primary AWARD-2 manuscript. 8 Likewise, observed total hypoglycaemia was consistently lower with dulaglutide compared to glargine, particularly in the high PPG subgroups. As expected, greater increases in glargine dose were observed at 52 weeks in subgroups with high FG, given that glargine was titrated according to FG, and thus a higher median dose was required to control a higher degree of fasting hyperglycaemia.
A limitation of this study was the post hoc and non-prespecified nature of the analysis. The duration of this study was limited to 78 weeks (52 weeks was the primary endpoint), which may not represent the effects of long-term use of dulaglutide. Additionally, this post hoc analysis included small sample sizes, especially for the low FG/high PPG and high FG/low PPG subgroups. Due to the limited sample size, the median was chosen as the cut-off, which may have influenced the results as the glycaemic pattern was less strictly defined; thus, the data presented should be considered as hypothesisgenerating only. Lastly, as reported in the primary AWARD-2 study, the mean total daily glargine dose at 52 weeks was 29 units. 8 A central committee monitoring insulin adjustments was not employed, and thus, strict enforcement of the insulin titration algorithm was not accomplished. Although the total glargine dose was consistent with the average dose in other similar clinical trials, [17] [18] [19] it is possible that a stricter titration monitoring could have resulted in lower mean FG, leading to greater decrease in HbA1c with glargine.
In conclusion, this non-prespecified post hoc analysis of the AWARD-2 study shows that treatment with once-weekly dulaglutide is associated with improved glycaemic control regardless of baseline FG and PPG levels. These data suggest that this long-acting GLP-1RA
can be a valid treatment option in people with T2D at different levels of disease severity and with different glycaemic patterns.
